Skip to content
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
Qvanteq

Category: News

30. October 20177. February 20182017, News

Financing round completed

Qvanteq AG completed a financing round. It provides the company with sufficient cash to further develop its technology for vascular stents such as intracranial stents and flow diverters.

7. April 20177. February 20182017, News

Qvanteq’s technology in peer-reviewed journals

In vivo data involving Qvanteq’s surface technology was published in the April issue of the journal Eurointervention.

25. September 20167. February 20182016, News

QUEST I FIM study completed

Qvanteq AG today announced that its QUEST I study was completed. The technology has shown safety in humans.

30. July 20167. February 20182016, News

Qvanteq obtained government funding in the form of a new CTI/KTI project (19305.1 PFLS-LS)

The topic of this 18 month program is the “Investigation of in vitro response of human blood to Qvanteq’s anti-thrombotic and pro-healing surface technology applied on vascular stents”.  

30. September 20157. February 20182015, News

QUEST I clinical study, patient recruitment completed

Qvanteq AG today announced that it completed enrollment of QUEST I study patients.

Posts navigation

< 1 2 3 4 … 7 >

Recent News

  • Reduced thrombogenicity of surface-treated Nitinol implants steered by altered protein adsorption
  • Stop the activation of the blood coagulation cascade by your medical device
  • Make any surface antithrombotic
  • Qvanteq is using MedtechVault
  • In-vitro thrombogenicity screening capacity

Qvanteq AG

Technoparkstr. 1, 8005 Zürich, Switzerland
+41 44 500 98 90
info@qvanteq.com

More

  • Meet us
  • Subscribe
  • Contact
  • Disclaimer
Copyright Qvanteq AG